Cancer Biomarkers Market Updates by 2031
The cancer biomarkers market was valued at US$ 18,436.36 million in 2022 and is likely to reach US$ 34,857.12 million by 2031 it is estimated to grow at a CAGR of 11.1% during 2022-2031
Biomarker, a biological molecule, is found in blood, tissues, or other body fluids that is a sign of a standard or abnormal process. A biomarker is used to see how well the body responds to a treatment for a disease or condition.
Market Insights
New Product Launches and FDA Approvals along with Technological Advancement Drive Market Growth
Market players are manufacturing a wide range of cancer biomarkers that offer maximum advantages and early diagnosis. In April 2021, Amgen launched the Biomarker Assist, a program to help more patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) gain access to biomarker testing. Biomarker testing at the time of diagnosis is a critical first step in getting patients on the right treatment. Through Biomarker Assist, eligible patients may save on biomarker testing.
Moreover, in March 2022, Vela Diagnostics has launched new focused (60 genes) and comprehensive (525 genes) next-generation sequencing (NGS)-based panels to detect RNA and DNA cancer biomarkers from formalin-fixed paraffin-embedded (FFPE) tissue specimens. The new pan-cancer gene panels include the focused OncoKey SL 60 Plus Panel and comprehensive OncoKey SL 525 Plus Panel.
Furthermore, in December 2019, BioGenex launched three new primary immunohistochemistry (IHC) antibodies including CD8A, CD163, and CD56 for cancer diagnosis.
Additionally, recent advances in cancer immunotherapies have emerged in long-lasting clinical responses in patients. Cancer immunotherapies are rapidly replacing traditional treatment standards and expanding the therapeutic landscape for cancer patients. Researchers are focused on finding molecules in the blood that can signal the appearance of cancers. For the diagnosis of ovarian and prostate cancers, the cancer antigen (CA)125 and prostate-specific antigen (PSA) are used alongside other tests.
Additionally, advancements in high-throughput omics technologies, including genomics, proteomics, transcriptomics, and metabolomics, accelerated the pace of biomarker discovery. Recently, the concept of identifying circulating tumor DNA through a liquid biopsy has moved to clinical reality. The Society for Immunotherapy of Cancer (SITC) reconvened biomarker for an Immune Task Force to review the state-of-the-art technologies, identify current hurdlers, and make recommendations for the field. Therefore, recent technological advancement has enabled many potential biomarkers and renewed in developing new biomarkers and drive the growth of cancer biomarkers market.
Strategic Insights
Market Insights - Opportunities
Emerging Markets in Developing Countries to Provide Lucrative Opportunities for Market during Forecast Period
Emerging markets such as Asia Pacific are creating ample opportunities for significant market players to expand their business. Most of the major players focus on emerging countries such as India, China, and others owing to a large number of cancer patients and the growth of medical tourism in developing countries. Most of the emerging countries are preferred place for medical tourism.
As per the Australian Institute of Health and Welfare, 151,000 new cases of cancer are diagnosed in 2021. Furthermore, according to the Malaysia Healthcare Travel Council, in 2021, more than 2 million visited Malaysia for healthcare purposes doubling the medical tourism revenue to ~680 million. The low cost of surgeries and advanced technologies with less waiting time for procedures in the region are likely to boost the demand for cancer biomarkers.
Therefore, growing medical tourism in emerging countries and increasing cancer prevalence in Asia Pacific are anticipated to provide significant growth opportunities to the players operating in the cancer biomarkers market during the forecast period.
Biomarker Type-Based Insights
The cancer biomarkers market, based on biomarker type, is segmented into genetic biomarkers, protein biomarkers, and others. The protein biomarker segment held the largest share of the market in 2022 and is anticipated to register the highest growth rate during the forecast period.
Profiling Technology-Based Insights
The cancer biomarkers market, by profiling technology, is segmented into omics technologies, imaging technologies, immunoassays, cytogenetics, and bioinformatics. The omics technologies segment held the largest market share in 2022 and is anticipated to register the highest growth rate during 2022–2031.
Cancer Type-Based Insights
The cancer biomarkers market, based on cancer type, is segmented into breast cancer, lung cancer, prostate cancer, leukemia, bladder cancer, and others. In 2022, the other segment held the largest share of the market. However, the lung cancer segment is expected to register the fastest growth rate in the coming years.
Application-Based Insights
Based on application, the cancer biomarkers market is segmented into diagnostics, research and development, prognostics, and others. In 2022, the prognostics segment held the largest share of the market. Also, the same segment is anticipated to register the highest CAGR during the forecast period.
Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the cancer biomarkers market. A few recent key market developments are listed below:
- In March 2022, Vela Diagnostics has launched new focused (60 genes) and comprehensive (525 genes) next-generation sequencing (NGS)-based panels to detect RNA and DNA cancer biomarkers from formalin-fixed paraffin-embedded (FFPE) tissue specimens. The new pan-cancer gene panels include the focused OncoKey SL 60 Plus Panel and comprehensive OncoKey SL 525 Plus Panel.
- In March 2022, the National Cancer Institute, part of the National Institutes of Health, has launched the Molecular Characterization Initiative for pediatric tumors. This program offers tumor molecular characterization, also called biomarker testing, to children, adolescents, and young adults with newly diagnosed central nervous system tumors who are being treated at hospitals that are affiliated with the Children’s Oncology Group
- In December 2019, BioGenex launched three new primary immunohistochemistry (IHC) antibodies including CD8A, CD163, and CD56 for cancer diagnosis.
- In May 2021, GE Healthcare acquires oncology biomarker maker Zionexa to further develop molecular imaging agents for cancer treatment. The company will develop and commercialise the Zionexa biomarkers and positron emission tomography (PET) imaging agent, Cerianna (fluoroestradiol F-18). Cerianna is approved by the US Food and Drug Administration for use as an adjunct to biopsy for identifying estrogen receptor (ER) positive lesions. It can aid in choosing the best therapies for recurrent or metastatic breast cancer patients.
- In April 2021, Amgen launched the Biomarker Assist, a program to help more patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) gain access to biomarker testing. Biomarker testing at the time of diagnosis is a critical first step in getting patients on the right treatment. Through Biomarker Assist, eligible patients may save on biomarker testing.
Company Profiles
- Thermo Fisher Scientific Inc
- F. Hoffmann-La Roche Ltd
- Illumina Inc
- Bio-Rad Laboratories Inc
- QIAGEN
- bioMérieux Inc
- Creative Diagnostics Hologic Inc
- Myriad Genetic Inc
- Quest Diagnostics
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Biomarker Type, Profiling Technology, Cancer Type, and Application
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Unfavorable regulatory and reimbursement scenario is the major factor hindering the market growth.
Based on biomarker types, the protein biomarker segment held largest share of the market and protein biomarker segment is projected to register the highest CAGR during the forecast period.
The cancer biomarkers report contains forecast of 2019 to 2027.
The key factors that are driving growth of the market are growing cancer prevalence across the globe, new product launches and FDA approvals, and technological advancements.
National Cancer Institute defined biomarker as a biological molecule found in blood, or tissues or other body fluids that is a sign of a standard or abnormal process. A biomarker is employed to ascertain however well the body responds to a treatment for a malady or condition. Cancer biomarkers area unit the molecules that aid within the examination similarly because the treatment of various kinds of cancer. These molecules are often evaluated by aggregation samples like stool, neoplasm tissue, blood, urine, or alternative tissues or bodily fluids.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Cancer Biomarkers Market – By Biomarker Type
1.3.2 Global Cancer Biomarkers Market – By Profiling Technology
1.3.3 Global Cancer biomarkers Market – By Cancer Type
1.3.4 Global Cancer biomarkers Market – By Application
1.3.5 Global Cancer biomarkers Market – By Geography
2. Global Cancer biomarkers Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Global Cancer biomarkers Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Cancer Biomarkers Market - North America PEST Analysis
4.2.2 Cancer Biomarkers Market - Europe PEST Analysis
4.2.3 Cancer Biomarkers Market – Asia Pacific PEST Analysis
4.2.4 Cancer Biomarkers Market – Middle East & Africa PEST Analysis
4.2.5 Cancer Biomarkers Market – South and Central America PEST Analysis
5. Global Cancer Biomarkers Market – Key Industry Dynamics
5.1.1 Growing Cancer Prevalence Across The Globe
5.1.2 New Product Launches & FDA Approvals
5.1.3 Technological Advancements
5.2 Key Market Restraints
5.2.1 Unfavourable Regulatory and Reimbursement Scenario
5.3 Key Market Opportunities
5.3.1 Emerging Markets in Developing Countries
5.4 Future Trends
5.4.1 Inclination Towards Personalized Medicine
5.5 Impact Analysis
6. Cancer biomarkers Market – Global Analysis
6.1 Global Cancer biomarkers Market Revenue Forecasts And Analysis
6.2 Global Cancer biomarkers Market, By Geography - Forecasts And Analysis
6.3 Performance of Key Players
7. Cancer biomarkers Market Revenue And Forecasts To 2027 – Biomarker Type
7.1 Overview
7.2 Global Cancer Biomarkers Market Share by Biomarker Type 2018 & 2027 (%)
7.3 Genetic Biomarkers
7.3.1 Overview
7.3.2 Genetic Biomarkers Market Revenue and Forecast to 2027 (US$ Mn)
7.4 Protein Biomarkers
7.4.1 Overview
7.4.2 Protein Biomarkers Market Revenue and Forecast to 2027 (US$ Mn)
7.5 Other Cancer Biomarkers
7.5.1 Overview
7.5.2 Other Cancer Biomarkers Market Revenue and Forecast to 2027 (US$ Mn)
8. Cancer Biomarkers Market Analysis And Forecasts To 2027 – Profiling Technology
8.1 Overview
8.2 Global Cancer Biomarkers Market Share by Profiling Technology 2018 & 2027 (%)
8.3 Omics Technologies
8.3.1 Overview
8.3.2 Omics Technologies Market Revenue and Forecast to 2027 (US$ Mn)
8.4 Imaging Technologies
8.4.1 Overview
8.4.2 Imaging Technologies Market Revenue and Forecast to 2027 (US$ Mn)
8.4.3 Ultrasound
8.4.3.1 Overview
8.4.3.2 Ultrasound Market Revenue and Forecast to 2027 (US$ Mn)
8.4.4 Computed Tomography (CT)
8.4.4.1 Overview
8.4.4.2 Computed Tomography (CT) Market Revenue and Forecast to 2027 (US$ Mn)
8.4.5 Magnetic Resonance Imaging (MRI)
8.4.5.1 Overview
8.4.5.2 Global Magnetic Resonance Imaging (MRI)Market Revenue and Forecasts to 2027 (US$ Mn)
8.4.6 Positron Emission Tomography (PET) Market
8.4.6.1 Overview
8.4.6.2 Global Positron Emission Tomography (PET) Market Revenue and Forecasts to 2027 (US$ Mn)
8.5 Immunoassays
8.5.1.1 Overview
8.5.1.2 Immunoassays Market Revenue and Forecast to 2027 (US$ Mn)
8.6 Cytogenetics
8.6.1 Overview
8.6.2 Cytogenetics Market Revenue and Forecast to 2027 (US$ Mn)
8.7 Bioinformatics
8.7.1 Overview
8.7.2 Bioinformatics Market Revenue and Forecast to 2027 (US$ Mn)
9. Global Cancer biomarkers Market Revenue And Forecasts To 2027 – by Cancer Type
9.1 Overview
9.2 Global Cancer Biomarkers Market, By Cancer Type 2018 & 2027 (%)
9.3 Breast Cancer Market
9.3.1 Overview
9.3.2 Global Breast Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
9.4 Lung Cancer Market
9.4.1 Overview
9.4.2 Global Lung Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
9.5 Prostate Cancer Market
9.5.1 Overview
9.5.2 Global Prostate Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
9.6 Leukemia Market
9.6.1 Overview
9.6.2 Global Leukemia Market Revenue and Forecasts to 2027 (US$ Mn)
9.7 Bladder Cancer Market
9.7.1 Overview
9.7.2 Global Bladder Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
9.8 Other Cancer Market
9.8.1 Overview
9.8.2 Global Other Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
10. Global Cancer biomarkers Market Revenue And Forecasts To 2027 – by Application
10.1 Overview
10.2 Global Cancer Biomarkers Market, By Application 2018 & 2027 (%)
10.3 Diagnostics Market
10.3.1 Overview
10.3.2 Global Diagnostics Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
10.4 Research and Development Market
10.4.1 Overview
10.4.2 Global Research and Development Market Revenue and Forecasts to 2027 (US$ Mn)
10.5 Prognostics Market
10.5.1 Overview
10.5.2 Global Prognostics Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
10.6 Others Market
10.6.1 Overview
10.6.2 Global Others Market Revenue and Forecasts to 2027 (US$ Mn)
11. Cancer Biomarkers Market Revenue and Forecasts to 2027 – Geographical Analysis
11.1 North America Cancer Biomarkers Market Revenue And Forecasts To 2027
11.1.1 North America Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.1.2 North America Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
11.1.3 North America Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
11.1.3.1 North America Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
11.1.4 North America Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
11.1.5 North America Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
11.1.6 North America Cancer Biomarkers Market Revenue and Forecasts to 2027, By Country (%)
11.1.7 US Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.1.7.1 US Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.1.7.2 US Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
11.1.7.3 US Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
11.1.7.3.1 US Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
11.1.7.4 US Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
11.1.7.5 US Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
11.1.8 Canada Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.1.8.1 Canada Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.1.8.2 Canada Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
11.1.8.3 Canada Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
11.1.8.3.1 Canada Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
11.1.8.4 Canada Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
11.1.8.5 Canada Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
11.1.9 Mexico Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.1.9.1 Mexico Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.1.9.2 Mexico Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
11.1.9.3 Mexico Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
11.1.9.3.1 Mexico Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
11.1.9.4 Mexico Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
11.1.9.5 Mexico Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
11.2 Europe Cancer Biomarkers Market Revenue And Forecasts To 2027
11.2.1 Europe Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.2 Europe Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
11.2.3 Europe Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
11.2.3.1 Europe Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
11.2.4 Europe Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
11.2.5 Europe Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
11.2.6 Europe Cancer Biomarkers Market Revenue and Forecasts to 2027, By Country (%)
11.2.7 UK Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.7.1 UK Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.7.2 UK Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
11.2.7.3 UK Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
11.2.7.3.1 UK Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
11.2.7.4 UK Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
11.2.7.5 UK Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
11.2.8 Germany Cancer biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.8.1 Germany Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.8.2 Germany Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
11.2.8.3 Germany Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
11.2.8.3.1 Germany Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
11.2.8.4 Germany Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
11.2.8.5 Germany Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
11.2.9 France Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.9.1 France Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.9.2 France Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
11.2.9.3 France Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
11.2.9.3.1 France Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
11.2.9.4 France Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
11.2.9.5 France Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
11.2.10 Italy Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.10.1 Italy Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.10.2 Italy Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
11.2.10.3 Italy Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
11.2.10.3.1 Italy Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
11.2.10.4 Italy Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
11.2.10.5 Italy Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
11.2.11 Spain Cancer biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.11.1 Spain Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.11.2 Spain Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
11.2.11.3 Spain Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
11.2.11.3.1 Spain Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
11.2.11.4 Spain Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
11.2.11.5 Spain Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
11.3 Asia Pacific Cancer Biomarkers Market Revenue And Forecasts To 2027
11.4 Asia Pacific Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.4.1 Asia Pacific Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
11.4.2 Asia Pacific Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
11.4.2.1 Asia Pacific Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
11.4.3 Asia Pacific Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
11.4.4 Asia Pacific Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
11.4.5 Asia Pacific Cancer Biomarkers Market Revenue and Forecasts to 2027, By Country (%)
11.4.6 Japan Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.4.6.1 Japan Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.4.6.2 Japan Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
11.4.6.3 Japan Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
11.4.6.3.1 Japan Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
11.4.6.4 Japan Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
11.4.6.5 Japan Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
11.4.7 China Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.4.7.1 China Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.4.7.2 China Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
11.4.7.3 China Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
11.4.7.3.1 China Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
11.4.7.4 China Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
11.4.7.5 China Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
11.4.8 India Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.4.8.1 India Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.4.8.2 India Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
11.4.8.3 India Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
11.4.8.3.1 India Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
11.4.8.4 India Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
11.4.8.5 India Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
11.4.9 South Korea Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.4.9.1 South Korea Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.4.9.2 South Korea Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
11.4.9.3 South Korea Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
11.4.9.3.1 South Korea Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
11.4.9.4 South Korea Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
11.4.9.5 South Korea Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
11.4.10 Australia Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.4.10.1 Australia Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.4.10.2 Australia Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
11.4.10.3 Australia Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
11.4.10.3.1 Australia Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
11.4.10.4 Australia Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
11.4.10.5 Australia Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
11.5 Middle East & Africa Cancer biomarkers Market Revenue And Forecasts To 2027
11.5.1 Middle East & Africa Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.5.2 Middle East & Africa Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
11.5.3 Middle East & Africa Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
11.5.3.1 Middle East & Africa Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
11.5.4 Middle East & Africa Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
11.5.5 Middle East & Africa Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
11.5.6 Middle East & Africa Cancer biomarkers Market Revenue and Forecasts to 2027, By Country (%)
11.5.7 UAE Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.5.7.1 UAE Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.5.8 UAE Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
11.5.9 UAE Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
11.5.9.1 UAE Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
11.5.10 UAE Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
11.5.11 UAE Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
11.5.12 Saudi Arabia Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.5.12.1 Saudi Arabia Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.5.13 Saudi Arabia Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
11.5.14 Saudi Arabia Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
11.5.14.1 Saudi Arabia Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
11.5.15 Saudi Arabia Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
11.5.16 Saudi Arabia Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
11.5.17 South Africa Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.5.17.1 South Africa Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.5.18 South Africa Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
11.5.19 South Africa Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
11.5.19.1 South Africa Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
11.5.20 South Africa Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
11.5.21 South Africa Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
11.6 South And Central America Cancer Biomarkers Market Revenue And Forecasts To 2027
11.6.1 South and Central America Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.6.2 South and Central America Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
11.6.3 South and Central America Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
11.6.3.1 South and Central America Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
11.6.4 South and Central America Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
11.6.5 South and Central America Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
11.6.6 South and Central America Cancer Biomarkers Market Revenue and Forecasts to 2027, By Country (%)
11.6.7 Argentina Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.6.7.1 Argentina Cancer biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.6.8 Argentina Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
11.6.9 Argentina Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
11.6.9.1 Argentina Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
11.6.10 Argentina Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
11.6.11 Argentina Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
11.6.12 Brazil Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.6.12.1 Brazil Cancer biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
11.6.13 Brazil Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
11.6.14 Brazil Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
11.6.14.1 Brazil Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
11.6.15 Brazil Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
11.6.16 Brazil Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
12. Cancer Biomarkers Market – Industry Landscape
12.1 Overview
12.2 Growth Strategies done by the companies in the Market, 2018 (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic developments
12.4.1 Overview
13. Cancer biomarkers Market–Key Company Profiles
13.1 Bio-Rad Laboratories, Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Financial Information
13.1.4 Product Portfolio
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Thermo Fisher Scientific, Inc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Financial Information
13.2.4 Product Portfolio
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 F. Hoffmann-La Roche Ltd.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Financial Overview
13.3.4 Product Portfolio
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.5 Qiagen N.V.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Financial Overview
13.5.4 Product Portfolio
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.7 Illumina, Inc.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Financial Overview
13.7.4 Product Portfolio
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Myriad Genetics, Inc.
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Financial Overview
13.8.4 Product Portfolio
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Hologic Inc.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Financial Overview
13.9.4 Product Portfolio
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Quest Diagnostics Incorporated
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Financial Overview
13.10.4 Product Portfolio
13.10.5 SWOT Analysis
13.10.6 Key Developments
13.11 BioMérieux SA
13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Financial Information
13.11.4 Product Portfolio
13.11.5 SWOT Analysis
13.11.6 Key Developments
13.12 Creative Diagnostics
13.12.1 Key Facts
13.12.2 Business Description
13.12.3 Financial Overview
13.12.4 Product Portfolio
13.12.5 SWOT ANALYSIS
13.12.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
Table 2. North America Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
Table 3. North America Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 4. North America Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
Table 5. North America Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
Table 6. US Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
Table 7. US Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
Table 8. US Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 9. US Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
Table 10. US Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
Table 11. Canada Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
Table 12. Canada Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
Table 13. Canada Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 14. Canada Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
Table 15. Canada Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
Table 16. Mexico Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
Table 17. Mexico Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
Table 18. Mexico Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 19. Mexico Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
Table 20. Mexico Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
Table 21. Europe Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
Table 22. Europe Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
Table 23. Europe Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 24. Europe Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
Table 25. Europe Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
Table 26. UK Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
Table 27. UK Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
Table 28. UK Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 29. UK Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
Table 30. UK Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
Table 31. Germany Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
Table 32. Germany Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
Table 33. Germany Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 34. Germany Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
Table 35. Germany Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
Table 36. France Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
Table 37. France Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
Table 38. France Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 39. France Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
Table 40. France Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
Table 41. Italy Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
Table 42. Italy Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
Table 43. Italy Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 44. Italy Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
Table 45. Italy Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
Table 46. Spain Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
Table 47. Spain Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
Table 48. Spain Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 49. Spain Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
Table 50. Spain Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
Table 51. Asia Pacific Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
Table 52. Asia Pacific Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
Table 53. Asia Pacific Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 54. Asia Pacific Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
Table 55. Asia Pacific Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
Table 56. Japan Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
Table 57. Japan Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
Table 58. Japan Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 59. Japan Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
Table 60. Japan Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
Table 61. China Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
Table 62. China Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
Table 63. China Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 64. China Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
Table 65. China Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
Table 66. India Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
Table 67. India Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
Table 68. India Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 69. India Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
Table 70. India Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
Table 71. South Korea Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
Table 72. South Korea Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
Table 73. South Korea Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 74. South Korea Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
Table 75. South Korea Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
Table 76. Australia Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
Table 77. Australia Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
Table 78. Australia Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 79. Australia Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
Table 80. Australia Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
Table 81. Middle East & Africa Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
Table 82. Middle East & Africa Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
Table 83. Middle East & Africa Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 84. Middle East & Africa Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
Table 85. Middle East & Africa Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
Table 86. UAE Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
Table 87. UAE Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
Table 88. UAE Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 89. UAE Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
Table 90. UAE Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
Table 91. Saudi Arabia Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
Table 92. Saudi Arabia Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
Table 93. Saudi Arabia Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 94. Saudi Arabia Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
Table 95. Saudi Arabia Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
Table 96. South Africa Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
Table 97. South Africa Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
Table 98. South Africa Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 99. South Africa Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
Table 100. South Africa Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
Table 101. South and Central America Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
Table 102. South and Central America Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
Table 103. South and Central America Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 104. South and Central America Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
Table 105. South and Central America Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
Table 106. Argentina Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
Table 107. Argentina Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
Table 108. Argentina Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 109. Argentina Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
Table 110. Argentina Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
Table 111. Brazil Cancer Biomarkers Market Revenue And Forecasts to 2027, By Biomarker Type (US$ Mn)
Table 112. Brazil Cancer Biomarkers Market Revenue And Forecasts to 2027, By Profiling Technology (US$ Mn)
Table 113. Brazil Imaging Technologies Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 114. Brazil Cancer Biomarkers Market Revenue And Forecasts to 2027, By Cancer Type (US$ Mn)
Table 115. Brazil Cancer Biomarkers Market Revenue And Forecasts to 2027, By Application (US$ Mn)
Table 116. Organic Developments Done By Companies
Table 117. Inorganic developments done by Companies
Table 118. Glossary of Terms, Cancer biomarkers Market
LIST OF FIGURES
Figure 1. Cancer Biomarkers Market Segmentation
Figure 2. Cancer Biomarkers Market Segmentation, by Region
Figure 3. Global Cancer biomarkers Market Overview
Figure 4. Protein Biomarker Segment Held Largest Share Of The Biomarker Type Segment In Cancer biomarkers Market
Figure 5. Asia Pacific Region Is Expected To Show Remarkable Growth During The Forecast Period
Figure 6. Global Cancer biomarkers Market, By Geography (US$ Mn)
Figure 7. Global Cancer Biomarkers Market- Leading Country Markets (US$ Mn)
Figure 8. Global Cancer biomarkers Market, Industry Landscape
Figure 9. Cancer Biomarkers Market - North America PEST Analysis
Figure 10. Cancer Biomarkers Market - Europe Pest Analysis
Figure 11. Cancer Biomarkers Market – Asia Pacific Pest Analysis
Figure 12. Cancer Biomarkers Market – Middle East & Africa Pest Analysis
Figure 13. Cancer Biomarkers Market – South and Central America PEST Analysis
Figure 14. Most Prevalent Forms of Cancers Globally, 2018
Figure 15. Cancer Biomarkers Market Impact Analysis of Driver and Restraints
Figure 16. Global Cancer biomarkers Market – Revenue Forecasts and Analysis – 2018- 2027
Figure 17. Global Cancer biomarkers Market – by Geography Forecasts and Analysis – 2018- 2027
Figure 18. Prominent Players in the Cancer biomarkers Market
Figure 19. Global Cancer Biomarkers Market Share by Biomarker Type 2018 & 2027 (%)
Figure 20. Genetic Biomarkers Market Revenue And Forecasts To 2027 (US$ Mn)
Figure 21. Protein Biomarkers Market Revenue And Forecasts To 2027 (US$ Mn)
Figure 22. Other Cancer Biomarkers Market Revenue And Forecasts To 2027 (US$ Mn)
Figure 23. Global Cancer Biomarkers Market Share by Profiling Technology 2018 & 2027 (%)
Figure 24. Omics Technologies Market Revenue And Forecasts To 2027 (US$ Mn)
Figure 25. Imaging Technologies Market Revenue And Forecasts To 2027 (US$ Mn)
Figure 26. Ultrasound Market Revenue And Forecasts To 2027 (US$ Mn)
Figure 27. Computed Tomography (CT)Market Revenue And Forecasts To 2027 (US$ Mn)
Figure 28. Global Magnetic Resonance Imaging (MRI)Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 29. Global Positron Emission Tomography (PET) Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 30. Immunoassays Market Revenue And Forecasts To 2027 (US$ Mn)
Figure 31. Cytogenetics Market Revenue And Forecasts To 2027 (US$ Mn)
Figure 32. Bioinformatics Market Revenue And Forecasts To 2027 (US$ Mn)
Figure 33. Global Cancer Biomarkers Market, by Cancer Type 2018 & 2027 (%)
Figure 34. Global Breast Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 35. Global Lung Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 36. Global Prostate Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 37. Global Leukemia Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 38. Global Bladder Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 39. Global Other Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 40. Global Cancer Biomarkers Market, by Application 2018 & 2027 (%)
Figure 41. Global Diagnostics Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 42. Global Research and Development Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 43. Global Prognostics Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 44. Global Others Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 45. North America Cancer Biomarkers Market Revenue Overview, by Country (2018) (US$ Mn)
Figure 46. North America Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 47. North America Cancer Biomarkers Market Revenue and Forecasts to 2027, By Country (%)
Figure 48. US Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 49. Canada Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 50. Mexico Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 51. Europe Cancer Biomarkers Market Overview, by Country (2018)
Figure 52. Europe Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 53. Europe Cancer Biomarkers Market Revenue and Forecasts to 2027, By Country (%)
Figure 54. UK Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 55. Germany Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 56. France Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 57. Italy Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 58. Spain Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 59. Asia Pacific Cancer Biomarkers Market Overview, by Country (2018)
Figure 60. Asia Pacific Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 61. Asia Pacific Cancer Biomarkers Market Revenue and Forecasts to 2027, By Country (%)
Figure 62. Japan Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 63. China Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 64. India Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 65. South Korea Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 66. Australia Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 67. Middle East & Africa Cancer biomarkers Market Revenue Overview, by Country, 2018 (US$ Mn)
Figure 68. Middle East & Africa Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 69. Middle East & Africa Cancer biomarkers Market Revenue and Forecasts to 2027, By Country (%)
Figure 70. UAE Cancer Biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 71. Saudi Arabia Cancer biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 72. South Africa Cancer biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 73. South and Central America Cancer Biomarkers Market Revenue Overview, by Country, 2018 (US$ Mn)
Figure 74. South and Central America Cancer biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 75. South and Central America Cancer Biomarkers Market Revenue and Forecasts to 2027, By Country (%)
Figure 76. Argentina Cancer biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 77. Brazil Cancer biomarkers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 78. Growth Strategies done by the companies in the Market, 2018 (%)
The List of Companies
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche Ltd.
- QIAGEN N.V.
- Illumina, Inc.
- Myriad Genetics, Inc.
- Hologic Inc.
- Quest Diagnostics Incorporated
- bioMérieux SA
- Creative Diagnostics
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For